Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COAST: aHSCT vs ocrelizumab or alemtuzumab in high-inflammatory RRMS
2016-001166-29Phase 2Terminated
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of autologous hematopoietic stem cells, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Time to treatment failure based on NEDA loss. Started Aug 2019; status: terminated.
02
Drugs
autologous hematopoietic stem cellsocrelizumabalemtuzumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2016-001166-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001166-29.